SEOUL, February 26 (AJP) - Biopharmaceutical company Celltrion said Thursday that it has taken steps to ensure its U.S. operations remain uninterrupted amid growing uncertainty over tariffs following a Supreme Court ruling last week.
In a statement, Celltrion said it is ready to respond regardless of how tariff-related issues are resolved after the U.S. Supreme Court found U.S. President Donald Trump's sweeping global tariffs policy unlawful.
Celltrion, which acquired U.S. drugmaker Eli Lilly's biopharmaceutical manufacturing facility in Branchburg, New Jersey, late last year, said it completed a full inspection and preparations for full operations by the end of January and began manufacturing this month.
The company said it has also begun procedures to manufacture its own products locally and plans to build a system linking production with its direct sales network to supply them across the U.S. as soon as possible.
Under its phased plans, Celltrion said it will hedge against tariff uncertainty by supplying the U.S. market with products manufactured at its Branchburg plant.
In a statement, Celltrion said it is ready to respond regardless of how tariff-related issues are resolved after the U.S. Supreme Court found U.S. President Donald Trump's sweeping global tariffs policy unlawful.
Celltrion, which acquired U.S. drugmaker Eli Lilly's biopharmaceutical manufacturing facility in Branchburg, New Jersey, late last year, said it completed a full inspection and preparations for full operations by the end of January and began manufacturing this month.
The company said it has also begun procedures to manufacture its own products locally and plans to build a system linking production with its direct sales network to supply them across the U.S. as soon as possible.
Under its phased plans, Celltrion said it will hedge against tariff uncertainty by supplying the U.S. market with products manufactured at its Branchburg plant.
Copyright ⓒ Aju Press All rights reserved.
